. . . . . . . "[Thus, we conclude that p53 deficiency and KRAS mutation activate the NF-?B signaling to control chemoresistance and tumorigenesis, and that the status of p53 and KRAS may be considered for the targeted therapy against NF-?B in lung cancer patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2017-02-19"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2017-10-17T13:14:59+02:00"^^ . . . . . . . . . . . "v5.0.0.0" . "v5.0.0" .